Stifel Financial
CRNX icon

Stifel Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Stifel Financial’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$765K Sell
21,058
-142
-0.7% -$6.34K ﹤0.01% 2609
2025
Q4 		$987K Sell
21,200
-533
-2% -$23.7K ﹤0.01% 2443
2025
Q3 		$905K Buy
21,733
+277
+1% +$8.86K ﹤0.01% 2453
2025
Q2 		$617K Buy
21,456
+12,458
+138% +$385K ﹤0.01% 2646
2025
Q1 		$302K Sell
8,998
-896
-9% -$33.5K ﹤0.01% 2967
2024
Q4 		$506K Sell
9,894
-144
-1% -$8.06K ﹤0.01% 2666
2024
Q3 		$513K Sell
10,038
-520
-5% -$26.8K ﹤0.01% 2665
2024
Q2 		$473K Buy
10,558
+346
+3% +$16K ﹤0.01% 2658
2024
Q1 		$478K Buy
+10,212
New +$400K ﹤0.01% 2640

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Stifel Financial's CRNX Position: Q1 2026 in Review

Stifel Financial reduced its Crinetics Pharmaceuticals (CRNX) stake by 0.67% in Q1 2026, selling an estimated $6.34K and leaving 21,058 shares worth $765K. The position accounts for ﹤0.01% of the portfolio, ranked #2609.

Stifel Financial first reported a position in CRNX in Q1 2024 and has held it in 9 quarters since. The position peaked at $987K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Stifel Financial held 21,058 shares of Crinetics Pharmaceuticals worth $765K as of Q1 2026.
  • Stifel Financial sold 142 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $6.34K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #2609 holding.
  • Stifel Financial first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Stifel Financial's Crinetics Pharmaceuticals position peaked at $987K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.